Chinese biotech company Jacobio Pharma announced on Monday that it had received approval from Chinese regulatory authorities for the registration phase-3 clinical trial of a combination therapy using its SHP2 inhibitor drug candidate JAB-3312.
SHP2 inhibitors are expected worldwide to have a substantial clinical effect in cancer and immunity disease treatment, and the approval made JAB-3312 the first SHP2 inhibitor to enter the phase-3 clinical study globally.
The approved clinical study in China is designed to evaluate the efficacy and safety of JAB-3312 in combination with the company's other investigational drug candidate KRAS G12C inhibitor glecirasib, for treating first-line non-small cell lung cancer patients with KRAS G12C mutations.
The control arm is the current standard treatment for first-line non-small cell lung cancer, which is the combination therapy of PD-1 antibody and chemotherapy.
Analysis: Larson enters conversation with Verstappen as best drivers in the world
339 Ghanaian students receive scholarship for Chinese language proficiency
Corbin Burnes labors through 5 innings against his former team, but keeps Orioles close vs. Brewers
Ancient pottery, kilns and wells unearthed in north China ruins
Six killed in a 'foiled coup' in Congo, the army says
Neil Brownsword: Exploring exchanges between China and the West through ceramics
Concert showcases Chinese traditional music in New Zealand
Biden says Brown v. Board of Education ruling was about more than education
Neil Brownsword: Exploring exchanges between China and the West through ceramics
Amtrak train hits pickup truck in upstate New York, 3 dead including child
Neil Brownsword: Exploring exchanges between China and the West through ceramics